On (b)(6) 2023 siemens released an urgent medical device correction communication to customers.Siemens healthcare diagnostics inc.Has determined that two drugs, perhexiline maleate and atomoxetine hydrochloride, may interfere with sodium results that are reported on the rapidpoint 500 and rapidpoint 500e blood gas systems.The presence of perhexiline maleate and atomoxetine hydrochloride has the potential to cause erroneously elevated sodium results which may lead to unrecognized hyponatremia and/or the inappropriate treatment of hypernatremia.Hyponatremia is associated with significant symptoms including nausea, malaise, headache, lethargy, obtundation and eventually seizures, coma, and respiratory arrest.Mitigations include the geographically restricted use of perhexiline maleate (which is mostly used in australia and new zealand), the short time-interval testing needs to occur after drug dosing for atomoxetine hydrochloride due to its short half-life, correlation of results with other electrolyte results such as chloride, historical sodium results, and the clinical history of the patient.Siemens healthcare diagnostics will be revising the rapidpoint 500 and rapidpoint 500e system operator's guide with information on the interfering substances.Once the revisions are completed, they will be available in siemens healthineers document library.
|